KSQ 001
Alternative Names: KSQ-001; KSQ-001EX; KSQ-001EX eTILLatest Information Update: 23 Feb 2024
At a glance
- Originator KSQ Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Jan 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT06237881)
- 29 Nov 2023 US FDA approves IND application for KSQ-001EX in Solid tumours
- 06 Sep 2023 KSQ Therapeutics plans a phase I/II for melanoma, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC)